MedTrace Logo

Towards the Validation of a New Blood Biomarker for the Early Diagnosis of Parkinson's Disease

NCT05385315 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2024-12-11

No results posted yet for this study

Summary

The investigators have recently discovered a metabolic biomarker which predicts Parkinson's disease (PD) at the early stages in patients and in animal models. The aim of BIOPARK is to investigate how the biomarker evolves in advanced PD stage, when diagnosis confirmation is higher, an in de novo PD patients who come from a different geographical area than those of the publication (since it is known that the metabolome is largely influenced by lifestyle). They will also evaluate if the biomarker is able to distinguish patients with a parkinsonian syndrome often confused with parkinson's disease, i.e. Multiple System Atrophy (MSA).

Conditions

  • Parkinson Disease

Sponsors & Collaborators

  • Grenoble Institut des Neurosciences

    collaborator OTHER

  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • Elena Moro · University Hospital, Grenoble

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-13
Primary Completion
2025-10-16
Completion
2025-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05385315 on ClinicalTrials.gov